Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the appointment of David A. Roth, M.D., as senior vice president, clinical development and medical affairs. In this newly created role, Dr. Roth will have responsibility for the clinical development organization and clinical operations, and he will also build and oversee the medical affairs function. Dr. Roth will serve as a member of Infinity’s executive leadership team and will report to Pedro Santabarbara, M.D., Ph.D., the company’s chief medical officer. Dr. Roth brings to Infinity over 20 years of experience in hematology and oncology research and development.
“It’s a pleasure to welcome David to Infinity. He holds a distinguished track record spanning both industry and academia. His appointment substantially enhances the depth and breadth of Infinity’s hematology and oncology expertise as we rapidly advance our lead program, IPI-145, toward late-stage development and potential registration,” stated Dr. Santabarbara. “David’s experience encompasses both early-stage and registration-phase programs, and the Infinity team looks forward to his contributions as we work to advance and expand our pipeline.”
“Infinity’s PI3K-delta,gamma inhibitor, IPI-145, has the potential to help transform the treatment landscape for patients with hematologic malignancies, and I am pleased to join Infinity at such an exciting time,” commented Dr. Roth. “Infinity has a history grounded in science and academic collaborations, and I’m delighted to be a part of this team as we strive to bring important new treatment options to patients and their physicians.”
Dr. Roth joins Infinity following more than ten years with Pfizer Inc. and Wyeth Pharmaceuticals. At Pfizer, he most recently served as a vice president in Pfizer’s oncology business unit. Dr. Roth joined Pfizer from Wyeth, where he held the role of assistant vice president, clinical research & development and global therapeutic area director of hematology. While at Pfizer and Wyeth, Dr. Roth contributed to the successful regulatory approval of several products, including Bosulif ® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha ® and ReFacto AF ® for the treatment of hemophilia A, and BeneFIX ® for the treatment of hemophilia B. Dr. Roth also led the early development of palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER positive advanced breast cancer. During his tenure at Pfizer and Wyeth, Dr. Roth also co-chaired Pfizer’s oncology research and development board and served on several oncology and hematology R&D leadership teams and governance committees.In addition to his extensive industry experience, Dr. Roth is an accomplished academic researcher and clinical practitioner. He received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology where he remains on the Affiliated Faculty.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts